MEI Pharma, Inc. (MEIP)

[bUrRpPPP!]

MEI Pharma Announces $45 Million Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 10, 2014 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it plans to offer up to $45,000,000 of shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.

The Company plans to use the net proceeds of the offering, together with other available funds, to progress the clinical development programs for Pracinostat in acute myeloid leukemia and for other general corporate purposes.

BofA Merrill Lynch is acting as sole book-running manager for the offering. Cowen and Company and Stifel are acting as co-lead managers.

The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.